Total Payments
$40,580
2024 Payments
$37,272
Companies
23
Transactions
96
Medicare Patients
829
Medicare Billing
$104,819
Payment Breakdown by Category
Other$33,492 (82.5%)
Food & Beverage$2,774 (6.8%)
Travel$2,456 (6.1%)
Consulting$1,800 (4.4%)
Education$57.89 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,147 | 9 | 66.9% |
| Honoraria | $6,345 | 1 | 15.6% |
| Food and Beverage | $2,774 | 78 | 6.8% |
| Travel and Lodging | $2,456 | 4 | 6.1% |
| Consulting Fee | $1,800 | 1 | 4.4% |
| Education | $57.89 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Madrigal Pharmaceuticals | $36,771 | 23 | $0 (2024) |
| Echosens North America, Inc. | $1,800 | 1 | $0 (2023) |
| Gilead Sciences, Inc. | $533.65 | 12 | $0 (2024) |
| ABBVIE INC. | $467.52 | 25 | $0 (2024) |
| Janssen Biotech, Inc. | $168.39 | 3 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $156.50 | 8 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $127.79 | 1 | $0 (2018) |
| Biocompatibles, Inc. | $97.46 | 1 | $0 (2019) |
| Mallinckrodt Hospital Products Inc. | $66.51 | 2 | $0 (2024) |
| Braintree Laboratories, Inc. | $59.75 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,272 | 45 | Madrigal Pharmaceuticals ($36,771) |
| 2023 | $2,422 | 26 | Echosens North America, Inc. ($1,800) |
| 2022 | $219.97 | 9 | Gilead Sciences, Inc. ($77.99) |
| 2021 | $192.34 | 9 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($80.33) |
| 2019 | $331.42 | 5 | Gilead Sciences, Inc. ($195.25) |
| 2018 | $127.79 | 1 | Merck Sharp & Dohme Corporation ($127.79) |
| 2017 | $14.75 | 1 | AbbVie, Inc. ($14.75) |
All Payment Transactions
96 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Honoraria | Cash or cash equivalent | $6,345.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $113.73 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $73.58 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $58.09 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $422.62 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $210.80 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $57.83 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $45.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $11.41 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $1.43 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/14/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/12/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/04/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $30.56 | General |
| Category: VIROLOGY | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/24/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,878.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/24/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $885.58 | General |
| Category: LIVER DISEASE | ||||||
| 10/24/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $149.62 | General |
| Category: LIVER DISEASE | ||||||
| 10/23/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.07 | General |
| 10/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,763.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Gastroenterology | ||||||
| 10/02/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,878.00 | General |
| Category: LIVER DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 296 | 380 | $143,904 | $34,465 |
| 2022 | 7 | 196 | 238 | $121,092 | $20,441 |
| 2021 | 3 | 54 | 68 | $34,139 | $6,176 |
| 2020 | 9 | 283 | 550 | $144,337 | $43,736 |
Total Patients
829
Total Services
1,236
Medicare Billing
$104,819
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 61 | 109 | $39,313 | $10,304 | 26.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 59 | $31,008 | $7,905 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 79 | $30,138 | $6,969 | 23.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 46 | 50 | $20,890 | $3,459 | 16.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $13,964 | $3,435 | 24.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 13 | 14 | $7,285 | $2,060 | 28.3% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 39 | 41 | $1,306 | $332.40 | 25.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $21,294 | $4,614 | 21.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 44 | $16,896 | $3,890 | 23.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 39 | $12,051 | $3,225 | 26.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 44 | $9,460 | $2,531 | 26.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 22 | $9,020 | $2,410 | 26.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 30 | 35 | $37,005 | $2,246 | 6.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $15,366 | $1,525 | 9.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 31 | 31 | $15,748 | $3,836 | 24.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 26 | $5,642 | $1,524 | 27.0% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 11 | 11 | $12,749 | $815.96 | 6.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 68 | 256 | $65,702 | $21,568 | 32.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 31 | 104 | $18,502 | $5,907 | 31.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 72 | 76 | $19,258 | $4,300 | 22.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 24 | 25 | $8,484 | $2,748 | 32.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $7,960 | $2,688 | 33.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 26 | 26 | $10,269 | $2,520 | 24.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 15 | 15 | $7,422 | $2,122 | 28.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 11 | $3,003 | $985.11 | 32.8% |
About Dr. Adnan Muhammad, M.D
Dr. Adnan Muhammad, M.D is a Transplant Hepatology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942242938.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adnan Muhammad, M.D has received a total of $40,580 in payments from pharmaceutical and medical device companies, with $37,272 received in 2024. These payments were reported across 96 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($27,147).
As a Medicare-enrolled provider, Muhammad has provided services to 829 Medicare beneficiaries, totaling 1,236 services with total Medicare billing of $104,819. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Transplant Hepatology
- Other Specialties Gastroenterology
- Location Tampa, FL
- Active Since 06/12/2006
- Last Updated 06/16/2021
- Taxonomy Code 207RT0003X
- Entity Type Individual
- NPI Number 1942242938
Products in Payments
- REZDIFFRA (Drug) $36,746
- FibroScan (Device) $1,800
- RINVOQ (Biological) $183.49
- XIFAXAN (Drug) $156.50
- MAVYRET (Drug) $141.87
- BRIDION (Drug) $127.79
- Vemlidy (Drug) $119.74
- STELARA (Biological) $117.65
- THERASPHERE-BIO (Device) $97.46
- Epclusa (Drug) $77.99
- TERLIVAZ (Drug) $66.51
- SUTAB (Drug) $59.75
- REMICADE (Biological) $50.74
- Heplisav-B (Drug) $46.71
- DUPIXENT (Biological) $44.76
- SKYRIZI (Biological) $43.59
- LINZESS (Drug) $38.60
- Mavyret (Drug) $34.93
- VOWST (Biological) $32.22
- WATCHMAN (Device) $31.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.